Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 449

1.

Successful Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices Using Foam Sclerosant Followed by Glue Embolization of Gastrorenal Shunt via the Brachial Vein Approach in a Severely Obese Patient.

Tsuruya K, Koizumi J, Sekiguchi T, Hara T, Sekiguchi Y, Anzai K, Arase Y, Hirose S, Kagawa T.

Ann Vasc Dis. 2019 Dec 25;12(4):562-565. doi: 10.3400/avd.cr.19-00084.

2.

Usefulness of autotaxin for the complications of liver cirrhosis.

Shao X, Uojima H, Setsu T, Okubo T, Atsukawa M, Furuichi Y, Arase Y, Hidaka H, Tanaka Y, Nakazawa T, Kako M, Kagawa T, Iwakiri K, Terai S, Koizumi W.

World J Gastroenterol. 2020 Jan 7;26(1):97-108. doi: 10.3748/wjg.v26.i1.97.

3.

Circulating MicroRNA-122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD.

Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.

Hepatol Commun. 2019 Nov 5;4(1):66-76. doi: 10.1002/hep4.1445. eCollection 2020 Jan.

4.

Reply to Letter to the Editor (HEP-19-1897).

Arase Y, Kagawa T, Tanaka A.

Hepatology. 2019 Dec 21. doi: 10.1002/hep.31084. [Epub ahead of print]

PMID:
31863598
5.

Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C.

Ogasawara N, Saitoh S, Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Hepatol Res. 2019 Nov 30. doi: 10.1111/hepr.13467. [Epub ahead of print]

PMID:
31785120
6.

Reply to Letter to the Editor (HEP-19-1638).

Arase Y, Kagawa T.

Hepatology. 2019 Oct 19. doi: 10.1002/hep.30999. [Epub ahead of print]

PMID:
31628871
7.

Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver.

Ogasawara N, Saitoh S, Denpou H, Kinowaki K, Akuta N, Suzuki F, Hashimoto M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Fujii T, Kumada H.

Intern Med. 2019 Oct 17. doi: 10.2169/internalmedicine.3577-19. [Epub ahead of print]

8.

Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease.

Akuta N, Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Intern Med. 2019 Sep 18. doi: 10.2169/internalmedicine.3555-19. [Epub ahead of print]

9.

Efficacy and Safety of 3-Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases.

Arase Y, Tsuruya K, Hirose S, Ogiwara N, Yokota M, Anzai K, Deguchi R, Shiraishi K, Shirai T, Kagawa T.

Hepatology. 2019 Aug 20. doi: 10.1002/hep.30904. [Epub ahead of print] No abstract available.

PMID:
31429969
10.

Long-term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy.

Ogasawara N, Saitoh S, Akuta N, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Hepatol Res. 2019 Dec;49(12):1441-1450. doi: 10.1111/hepr.13418. Epub 2019 Oct 9.

PMID:
31373093
11.

Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy.

Suzuki H, Sezaki H, Suzuki F, Kasuya K, Sano T, Fujiyama S, Kawamura Y, Hosaka T, Akuta N, Saitoh S, Kobayashi M, Arase Y, Ikeda K, Suzuki Y, Kumada H.

Hepatol Res. 2019 Dec;49(12):1406-1413. doi: 10.1111/hepr.13415. Epub 2019 Aug 9.

PMID:
31347756
12.

Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis.

Sano T, Akuta N, Suzuki F, Kasuya K, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H.

Intern Med. 2019 Sep 15;58(18):2657-2662. doi: 10.2169/internalmedicine.2604-18. Epub 2019 Jun 7.

13.

Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Liver Fat Mass and Body Composition in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus.

Arase Y, Shiraishi K, Anzai K, Sato H, Teramura E, Tsuruya K, Hirose S, Deguchi R, Toyoda M, Mine T, Kagawa T.

Clin Drug Investig. 2019 Jul;39(7):631-641. doi: 10.1007/s40261-019-00785-6.

14.

Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.

Sezaki H, Suzuki F, Hosaka T, Fujiyama S, Kawamura Y, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

J Gastroenterol. 2019 Oct;54(10):916-927. doi: 10.1007/s00535-019-01575-9. Epub 2019 Mar 22.

PMID:
30903385
15.

Association of Thyrotropin Concentration with Chronic Kidney Disease in a Japanese General Population Cohort.

Toda A, Hara S, Kato M, Tsuji H, Arase Y.

Nephron. 2019;142(2):91-97. doi: 10.1159/000497326. Epub 2019 Feb 22.

PMID:
30799424
16.

The Lack of Hepatocyte Steatosis in Adult-onset Type II Citrullinemia Patients as Assessed by 7-year Interval Paired Biopsies.

Suzuki H, Kawamura Y, Kinowaki K, Akuta N, Kasuya K, Fujiyama S, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Suzuki F, Suzuki Y, Kumada H.

Intern Med. 2019 Jul 1;58(13):1891-1895. doi: 10.2169/internalmedicine.2374-18. Epub 2019 Feb 25.

17.

Association between Helicobacter pylori infection, eradication and diabetes mellitus.

Kato M, Toda A, Yamamoto-Honda R, Arase Y, Sone H.

J Diabetes Investig. 2019 Sep;10(5):1341-1346. doi: 10.1111/jdi.13011. Epub 2019 Feb 12.

18.

Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.

Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

Aliment Pharmacol Ther. 2019 Feb;49(4):457-471. doi: 10.1111/apt.15108. Epub 2019 Jan 20. Erratum in: Aliment Pharmacol Ther. 2019 Jul;50(2):234-235.

PMID:
30663078
19.

Relationship between response to lusutrombopag and splenic volume.

Uojima H, Arase Y, Itokawa N, Atsukawa M, Satoh T, Miyazaki K, Hidaka H, Sung JH, Kako M, Tsuruya K, Kagawa T, Iwakiri K, Horie R, Koizumi W.

World J Gastroenterol. 2018 Dec 14;24(46):5271-5279. doi: 10.3748/wjg.v24.i46.5271.

20.

Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus.

Akuta N, Kawamura Y, Watanabe C, Nishimura A, Okubo M, Mori Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Hepatol Res. 2019 May;49(5):531-539. doi: 10.1111/hepr.13304. Epub 2019 Feb 6.

PMID:
30577089
21.

Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases.

Ohya K, Saitoh S, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kinowaki K, Fujii T, Kondo F, Kumada H.

Hepatol Res. 2019 Jun;49(6):711-717. doi: 10.1111/hepr.13295. Epub 2019 Jan 8.

PMID:
30537443
22.

Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study.

Sorin Y, Ikeda K, Kawamura Y, Fujiyama S, Kobayashi M, Hosaka T, Sezaki H, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Liver Cancer. 2018 Oct;7(4):323-334. doi: 10.1159/000487311. Epub 2018 Mar 14.

23.

Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan.

Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.

BMC Gastroenterol. 2018 Nov 6;18(1):165. doi: 10.1186/s12876-018-0900-1.

24.

Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.

Akuta N, Suzuki F, Sezaki H, Kobayashi M, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Clin Microbiol. 2019 Jan 2;57(1). pii: e01463-18. doi: 10.1128/JCM.01463-18. Print 2019 Jan.

25.

Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites.

Arase Y, Kagawa T, Tsuruya K, Sato H, Teramura E, Anzai K, Hirose S, Deguchi R, Shiraishi K, Mine T.

Clin Drug Investig. 2019 Jan;39(1):45-54. doi: 10.1007/s40261-018-0714-5.

26.

No-touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection.

Kawamura Y, Ikeda K, Shindoh J, Kobayashi Y, Kasuya K, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Hashimoto M, Kumada H.

Hepatol Res. 2019 Feb;49(2):164-176. doi: 10.1111/hepr.13254. Epub 2018 Nov 6.

PMID:
30277295
27.

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.

Suzuki F, Hosaka T, Suzuki Y, Sezaki H, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H.

J Gastroenterol. 2019 Feb;54(2):182-193. doi: 10.1007/s00535-018-1502-y. Epub 2018 Aug 22.

PMID:
30136216
28.

Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.

Takeuchi Y, Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

Hepatol Res. 2019 Mar;49(3):256-263. doi: 10.1111/hepr.13242. Epub 2018 Sep 23.

PMID:
30125438
29.

Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.

Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2019 Jan;91(1):102-106. doi: 10.1002/jmv.25278. Epub 2018 Sep 3.

PMID:
30091810
30.

Circulating microRNA-122 levels are important predictor of hepatitis B virus surface antigen seroclearance.

Akuta N, Suzuki F, Kobayashi M, Hosaka T, Fujiyama S, Kawamura Y, Sezaki H, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2018 Oct;90(10):1586-1592. doi: 10.1002/jmv.25238. Epub 2018 Jul 10.

PMID:
29896794
31.

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis.

Kuwano T, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Saitoh S, Kobayashi M, Suzuki Y, Kobayashi M, Arase Y, Ikeda K, Kumada H.

Intern Med. 2018 Sep 1;57(17):2511-2515. doi: 10.2169/internalmedicine.0585-17. Epub 2018 Mar 30.

32.

Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trial.

Akuta N, Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K.

Hepatol Res. 2018 Sep;48(10):810-813. doi: 10.1111/hepr.13075. Epub 2018 Apr 24.

PMID:
29601141
33.

Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens.

Ogata F, Akuta N, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2018 Jun;90(6):1087-1093. doi: 10.1002/jmv.25047. Epub 2018 Feb 26.

PMID:
29427443
34.

Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies.

Akuta N, Watanabe C, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.

Hepatol Commun. 2017 Feb 27;1(1):46-52. doi: 10.1002/hep4.1019. eCollection 2017 Feb.

35.

Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.

Ohya K, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Kominami Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2018 May;90(5):919-925. doi: 10.1002/jmv.25023. Epub 2018 Jan 30.

PMID:
29315652
36.

Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome.

Fujiyama S, Saitoh S, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H.

BMC Gastroenterol. 2017 Oct 25;17(1):112. doi: 10.1186/s12876-017-0668-8.

37.

Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.

Ogasawara N, Kobayashi M, Akuta N, Kominami Y, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Suzuki F, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kobayashi M, Kumada H.

J Med Virol. 2018 Feb;90(2):313-319. doi: 10.1002/jmv.24950. Epub 2017 Sep 25.

PMID:
28906010
38.

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma.

Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, Sezaki H, Hosaka T, Akuta N, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Dig Dis Sci. 2017 Oct;62(10):2932-2942. doi: 10.1007/s10620-017-4739-z. Epub 2017 Sep 7.

PMID:
28884320
39.

Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus.

Osawa M, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Suzuki Y, Ikeda K, Kumada H.

J Med Virol. 2017 Dec;89(12):2144-2148. doi: 10.1002/jmv.24890. Epub 2017 Aug 31.

PMID:
28667756
40.

New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease.

Kawamura Y, Ikeda K, Arase Y, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Kumada H.

Intern Med. 2017;56(12):1459-1465. doi: 10.2169/internalmedicine.56.7830. Epub 2017 Jun 15.

41.

Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease.

Ogata F, Kobayashi M, Akuta N, Osawa M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K, Kumada H.

Oncology. 2017;93(2):92-98. doi: 10.1159/000470910. Epub 2017 Apr 28.

PMID:
28448999
42.

Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride.

Akuta N, Kumada H, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Suzuki F, Arase Y, Ikeda K.

Hepatol Res. 2018 Jan;48(1):45-50. doi: 10.1111/hepr.12894. Epub 2017 Apr 19.

PMID:
28322485
43.

The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.

Sezaki H, Suzuki F, Hosaka T, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

Liver Int. 2017 Sep;37(9):1325-1333. doi: 10.1111/liv.13384. Epub 2017 Mar 17.

PMID:
28178397
44.

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.

Akuta N, Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2017 Jul;89(7):1248-1254. doi: 10.1002/jmv.24767. Epub 2017 Feb 27.

PMID:
28079269
45.

Successful Eradication Therapy for Helicobacter pylori-positive Atrophic Gastritis at the Sixth Attempt: A Case Report.

Deguchi R, Shiraishi K, Arase Y, Dekiden M, Shimada H, Miyakita H, Ogimi T, Myojin K, Mine T.

Tokai J Exp Clin Med. 2016 Dec 20;41(4):233-235.

46.

Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma.

Akuta N, Kawamura Y, Suzuki F, Saitoh S, Arase Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Kobayashi M, Ikeda K, Kumada H.

BMC Gastroenterol. 2016 Dec 12;16(1):141.

47.

Potential of a no-touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intrasubsegmental recurrence of small and single hepatocellular carcinomas.

Kawamura Y, Ikeda K, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H.

Hepatol Res. 2017 Sep;47(10):1008-1020. doi: 10.1111/hepr.12838. Epub 2016 Dec 30.

PMID:
27862748
48.

Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment.

Shomura M, Kagawa T, Okabe H, Shiraishi K, Hirose S, Arase Y, Tsuruya K, Takahira S, Mine T.

BMC Cancer. 2016 Nov 11;16(1):878.

49.

Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.

Akuta N, Sezaki H, Suzuki F, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2017 Jan;89(1):91-98. doi: 10.1002/jmv.24592. Epub 2016 Jun 8.

PMID:
27256744
50.

Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.

Suzuki F, Suzuki Y, Hosaka T, Sezaki H, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H.

J Gastroenterol. 2017 May;52(5):641-651. doi: 10.1007/s00535-016-1270-5. Epub 2016 Oct 3.

PMID:
27699721

Supplemental Content

Support Center